Benefit–risk assessment of sonidegib and vismodegib in the treatment of locally advanced basal cell carcinoma
Background: Sonidegib and vismodegib are Hedgehog pathway inhibitors (HhIs) that play a relevant role in the management of locally advanced basal cell carcinoma (laBCC). This study compared the efficacy and safety of both HhIs based on their available data using effect size measures such as number n...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BioExcel Publishing Ltd
2022-07-01
|
| Series: | Drugs in Context |
| Subjects: | |
| Online Access: | https://www.drugsincontext.com/benefit-risk-assessment-of-sonidegib-and-vismodegib-in-the-treatment-of-locally-advanced-basal- cell-carcinoma |